-+ 0.00%
-+ 0.00%
-+ 0.00%
C4X Discovery to receive $13 million AstraZeneca milestone as NRF2 drug enters Phase I trial
Share
Listen to the news
C4X Discovery to receive $13 million AstraZeneca milestone as NRF2 drug enters Phase I trial
  • C4X Discovery to receive a $13 million milestone payment from AstraZeneca on 4 September 2026.
  • Payment triggered by AstraZeneca advancing AZD4916, an oral NRF2 activator licensed from C4X Discovery, into Phase I.
  • Deal signed in November 2022 provides up to $400 million in preclinical and clinical milestones.
  • Agreement also includes tiered mid-single digit royalties on future sales.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. C4X Discovery Holdings Ltd. published the original content used to generate this news brief on September 04, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending